ERBB2 and breast cancer: In solid tumors like breast cancer, preclinical models suggest that dual-target CAR-Ts may mitigate off-tumor cytotoxicity through selective targeting of co-expressed antigens, such as HER2 and MUC1, limiting systemic cytokine release and improving safety margins [174].